Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADALIMUMAB Cause Attention deficit/hyperactivity disorder? 37 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Attention deficit/hyperactivity disorder have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.0% of all adverse event reports for ADALIMUMAB.

37
Reports of Attention deficit/hyperactivity disorder with ADALIMUMAB
0.0%
of all ADALIMUMAB reports
0
Deaths
10
Hospitalizations

How Dangerous Is Attention deficit/hyperactivity disorder From ADALIMUMAB?

Of the 37 reports, 10 (27.0%) required hospitalization.

Is Attention deficit/hyperactivity disorder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 37 reports have been filed with the FAERS database.

What Other Side Effects Does ADALIMUMAB Cause?

Drug ineffective (71,926) Pain (37,514) Arthralgia (35,592) Rheumatoid arthritis (29,817) Fatigue (29,420) Injection site pain (28,679) Headache (19,891) Nausea (19,299) Rash (18,690) Pain in extremity (18,319)

What Other Drugs Cause Attention deficit/hyperactivity disorder?

METHYLPHENIDATE (127) VALPROATE (101) AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (88) LAMOTRIGINE (88) SODIUM OXYBATE (85) PAROXETINE (68) FINASTERIDE (65) QUETIAPINE (62) ARIPIPRAZOLE (59) FLUOXETINE (56)

Which ADALIMUMAB Alternatives Have Lower Attention deficit/hyperactivity disorder Risk?

ADALIMUMAB vs ADALIMUMAB-AACF ADALIMUMAB vs ADALIMUMAB-AATY ADALIMUMAB vs ADALIMUMAB-ADAZ ADALIMUMAB vs ADALIMUMAB-ADBM ADALIMUMAB vs ADALIMUMAB-AFZB

Related Pages

ADALIMUMAB Full Profile All Attention deficit/hyperactivity disorder Reports All Drugs Causing Attention deficit/hyperactivity disorder ADALIMUMAB Demographics